 |
| (사진=CJ) |
[Alpha Biz=(Chicago) Reporter Kim Jisun] CJ Group made a winning move to take the lead in developing new drugs using microbiome, a long-lasting microorganism.
In the development of microbiome-based anticancer drugs, the company acquired all of the candidates for the UK's leading global leader, 4D Pharma.
CJ Bioscience announced on the 27th that it has signed a contract to acquire all nine new drug candidates for 4D Pharma. CJ Bioscience is a subsidiary of CJ CheilJedang's pharmaceutical and healthcare division. After acquiring Cheonlab, a domestic microbiome company, in 2021, CJ Group has established a new corporation, CJ Bioscience, and is expanding its pharmaceutical and healthcare business last year.
It is the first time that a technology acquisition contract has been signed with a foreign company since the launch of the new corporation. The transaction amount was not disclosed. CJ Bioscience has decided to acquire two patents for 4D pharma candidate materials and new drug development platforms. After the acquisition process, the number of CJ Bioscience candidates with three candidate materials will increase to 12.
4D Pharma is developing anticancer drugs that are eaten as microbiome probiotics.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
